Australian Streptokinase Trial "ASK"


Phase 3 Results


The study found a nonsignificant trend toward unfavorable outcomes for streptokinase vs placebo and an excess of hematomas in the treated group,. Poor outcomes were confined to patients receiving therapy more than 3 hours after stroke onset. Streptokinase administration resulted in excess deaths in the group treated after 3 hours but not among those treated within 3 hours.